Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24 weeks versus 48 weeks of peginterferon alfa-2a plus ribavirin in HIV/HCV genotype 2 or 3 coinfected patients
2005-000203-34Phase 4Active
- Sponsor
- Enrique Ortega González
- Start
- Aug 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of peginterferon alfa-2a and ribavirin in hepatitis C virus infection (2 arms), sponsored by Enrique Ortega González. Started Aug 2012; status: active.
02
Drugs
peginterferon alfa-2aribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2005-000203-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000203-34.